2009 Innovative Research Grants

Over a three-year period, each investigator received up to $750,000 for a total of $10 million awarded for SU2C Innovative Research Grants. It is the hope that ideas for new SU2C Dream Teams will emerge from these Innovative Research Grants.

Watch the 2009 Innovative Research Grants recipients talk about their work and its potential impact on the treatment of people with cancer: 

The 13 SU2C Innovative Research Grant recipients in 2009 are:

An Emerging Tumor Suppressor Pathway in Human Cancer
Fernando D. Camargo, PhD, is principal member of the Harvard Stem Cell Institute; assistant professor at the Children's Hospital Boston and the Stem Cell Regenerative Biology Department at Harvard University.

Modeling Ewing Tumor Initiation in Human Neural Crest Stem Cells
Elizabeth R. Lawlor, MD, PhD, is Russell G. Adderley professor of pediatric oncology in the department of pediatrics at the University of Michigan.

Cancer Cell Specific, Self-Delivering Pro-Drugs
Matthew Levy, PhD, is assistant professor of biochemistry at Albert Einstein College of Medicine of Yeshiva University.

Targeted Inhibition of BCL6 for Leukemia Stem Cell Eradication
Markus Müschen, MD, is director of the Leukemia Research Program at Childrens Hospital Los Angeles and the Leukemia and Lymphoma Program in the University of Southern California Norris Comprehensive Cancer Center; associate professor of pediatrics, biochemistry, and molecular biology at the University of Southern California, Keck School of Medicine.

Identifying Solid Tumor Kinase Fusions via Exon Capture and 454 Sequencing
William Pao, MD, PhD, is global head of the oncology disease and translational area (DTA) at
Roche Pharma Research and Early Development (pRED).

Therapeutically Targeting the Epigenome in Aggressive Pediatric Cancers
Charles M. Roberts, MD, PhD, is assistant professor in the department of pediatrics at Harvard Medical School; assistant professor of pediatric oncology at the Dana-Farber Cancer Institute.

Endogenous Small Molecules that Regulate Signaling Pathways in Cancer Cells
Rajat Rohatgi, MD, PhD, is assistant professor in the department of medicine and oncology at the Stanford University School of Medicine.

Genetic Approaches for Next Generation of Breast Cancer Tailored Therapies
José M. Silva, PhD, assistant professor of pathology at the Institute for Cancer Genetics at Columbia University Medical Center.

Modulating Transcription Factor Abnormalities in Pediatric Cancer
Kimberly Stegmaier, MD, is co-director of the Pediatric Leukemia Program at the DFCI/CHB; assistant professor in the department of pediatrics at Harvard Medical School; independent investigator in pediatric oncology at the Dana-Farber Cancer Institute; and attending physician in pediatric hematology-oncology at the Children's Hospital Boston and the Dana-Farber Cancer Institute.

Noninvasive Molecular Profiling of Cancer via Tumor-Derived Microparticles
Muneesh Tewari, MD, PhD, is associate member in the Divisions of Human Biology, Clinical Research and Public Health Sciences at the Fred Hutchinson Cancer Research Center; and associate professor in the department of medicine at the School of Medicine, University of Washington.

A Transformative Technology to Capture and Drug New Cancer Targets
Loren D. Walensky, MD, PhD, is attending physician and assistant professor of pediatrics in the department of pediatric hematology/oncology at the Children's Hospital Boston, Dana-Farber Cancer Institute, Harvard Medical School.

Functional Oncogene Identification
David M. Weinstock, MD, is assistant professor in the department of medicine at Harvard Medical School; and assistant professor of medicine in the medical oncology service at Dana-Farber Cancer Institute.

Probing EBV-LMP-1's Transmembrane Activation Domain with Synthetic Peptide
Hang (Hubert) Yin, PhD, is assistant professor of chemistry and biochemistry and task force member of the Colorado Initiative in Molecular Biotechnology at the University of Colorado.

Updated: May 13, 2014